Evidence map›Paper›PMID 32300853›Full record

ReviewApplied microbiology and biotechnology2020

Transaminases for industrial biocatalysis: novel enzyme discovery.

Stephen A Kelly, Stefan Mix, Thomas S Moody, Brendan F Gilmore

Open access · hybridAbstract readReview
In one paragraph

Review in Applied microbiology and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 94 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Stephen A KellySchool of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, Northern Ireland.
Stefan MixDepartment of Biocatalysis & Isotope Chemistry, Almac, 20 Seagoe Industrial Estate, Craigavon, UK.
Thomas S MoodyDepartment of Biocatalysis & Isotope Chemistry, Almac, 20 Seagoe Industrial Estate, Craigavon, UK.
Brendan F GilmoreSchool of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, Northern Ireland. b.gilmore@qub.ac.uk.
Queen's University Belfast · GBAlmac (United Kingdom) · GBFarran Technology (Ireland) · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transaminases (TAms) are important enzymes for the production of chiral amines for the pharmaceutical and fine chemical industries. Novel TAms for use in these industries have been discovered using a range of approaches, including activity-guided methods and homologous sequence searches from cultured microorganisms to searches using key motifs and metagenomic mining of environmental DNA libraries. This mini-review focuses on the methods used for TAm discovery over the past two decades, analyzing the changing trends in the field and highlighting the advantages and drawbacks of the respective approaches used. This review will also discuss the role of protein engineering in the development of novel TAms and explore possible directions for future TAm discovery for application in industrial biocatalysis. KEY POINTS: • The past two decades of TAm enzyme discovery approaches are explored. • TAm sequences are phylogenetically analyzed and compared to other discovery methods. • Benefits and drawbacks of discovery approaches for novel biocatalysts are discussed. • The role of protein engineering and future discovery directions is highlighted.

Indexed as

BiocatalysisProtein EngineeringBacteriaIndustrial MicrobiologyMetagenomicsSubstrate SpecificityTransaminasesTransaminasesBiocatalysisChiral amineEnzyme discoveryMetagenomicsTransaminase

Identifiers

PMID32300853
PMCPMC7228992
OpenAlexW3016649947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.